Randomized phase III study of selpercatinib versus cabozantinib or vandetanib in advanced, kinase inhibitornaive, RET-mutant medullary thyroid cancer

Category Primary study
JournalANNALS OF ONCOLOGY
Year 2023
This article has no abstract
Epistemonikos ID: 55db1f23e8c5aed31402bb91754979498eb14b76
First added on: Dec 07, 2023